Analyst: AZ "worst performer" in pharma

So, Dresdner Kleinwort, tell us how you really feel about AstraZeneca. The investment bank, which just started covering AstraZeneca's stock, minced no words in its first report. The company's in "serious trouble," the analysts said, and quite possibly will be the worst performer in Big Pharma for the next eight years. At best, it'll manage a 1 percent growth in revenue, the analysts estimated; at worst, it'll drop 3 percent.

The basis for this bleak assessment? The company's three biggest sales-generators will get generic competition in the near future, and eight patents expire over the next eight years. Together that amounts to 60 percent of AZ's revenue. Even products ostensibly covered by patents through 2015, such as Nexium, Seroquel, and Crestor, face challenges that could expose them much, much sooner. The analysts weren't cheered by products coming up the pipeline, either.

Like all criticism, stock reports are subjective. Other analysts aren't as negative about AstraZeneca's prospects. And even the Kleinwort analyst said he was "mildly positive" about Crestor's approval for atherosclerosis treatment.

- read about Dresdner Kleinwort's rating at in-Pharma Technologist
- check out this assessment from New Ratings
- get more on Crestor from The Times

Related Articles:
AstraZeneca - Top 5 layoffs of 2007. Report
AstraZeneca lays out road map for recovery. Report
AstraZeneca announces restructuring and buyout. Report
AstraZeneca to continue ambitious deal-making. Report
AstraZeneca snares MedImmune in $15.6B buyout. Report

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Companies considering this avenue must think through potential implications despite the obvious attraction of early access for patients.

BD says a $1.2 billion investment in its pre-filled syringe business will add surge capacity needed to meet demand in future pandemics.

Ad Environment Matters for Message Receptivity